Skip to main content

ChEMBL 21 Released


We are pleased to announce the release of ChEMBL_21. This version of the database was prepared on 1st February 2016 and contains:

• 1,929,473 compound records
• 1,592,191 compounds (of which 1,583,897 have mol files)
• 13,968,617 activities
• 1,212,831 assays
• 11,019 targets
• 62,502 source documents

Data can be downloaded from the ChEMBL ftpsite or viewed via the ChEMBL interface. Please see ChEMBL_21 release notes for full details of all changes in this release.


CHANGES SINCE THE LAST RELEASE

In addition to the regular updates to the Scientific Literature, PubChem, FDA Orange Book and USP Dictionary of USAN and INN Investigational Drug Names this release of ChEMBL also includes the following new data:

* Data Depositions

Eight new deposited data sets have been included in ChEMBL_21. These include HepG2 cell viability data for the Gates Library Compound Collection from the University of Dundee, three depositions from groups screening the MMV Malaria Box (from TropIQ, Netherlands; Mahidol University, Thailand and Keele University, United Kingdom), anti-protozoal screening data from DNDi, anti-kinetoplastid screening data from GSK Tres Cantos, Leishmania screening data from St. Jude Children’s Hospital and carnitine palmitoyltransferase modulator screening data from Roche.

* Clinical Candidates

We have added >900 additional compounds in clinical development (phase I-III) to ChEMBL. These candidates mainly cover kinase, GPCR and nuclear hormone receptor targets. For each of these new candidates, we have curated likely efficacy targets (from a variety of sources such as scientific literature and pharmaceutical company pipeline documents) and added this information to the database. We have also updated the highest known development phase for compounds already in ChEMBL (such as monoclonal antibodies and compounds with USAN applications). We will continue to add further clinical candidate and target information in future releases (including targets for the existing monoclonal antibody candidates, and candidates for ion channel targets). Mechanism of action information for clinical candidates has been added to the 'Browse Drug Targets' tab on the ChEMBL interface, as well as the Compound and Target Report Cards:


* Drug Indications

We have identified indications for FDA approved drugs from a number of sources including Prescribing Information, ClinicalTrials.gov and the WHO ATC classification and mapped these to both MeSH disease identifiers and Experimental Factor Ontology disease identifiers. We will add further indications for compounds in clinical development in future ChEMBL releases. Drug indications can be viewed on Compound Report Cards and also on the 'Browse Drug Indications' tab:



* Drug Metabolism and Pharmacokinetic data

We have extracted drug metabolism and pharmacokinetic (PK) data from a number of data sources:
- Curated Drug Metabolism Pathways from a variety of literature/reference sources
- FDA Drug Approval Packages
- Drug Metabolism and Disposition Journal

Experimental assay data from these sources can be viewed via the Compound and Assay Report Cards and Bioactivity Summary views as usual. Further interface enhancements will be included in the near future to allow browsing of drug metabolism pathway data.

* GO Drug Target Slim:

We have created a Gene Ontology slim (GO slim) containing a subset of Gene Ontology terms that are well represented in protein targets from the ChEMBL database (see http://geneontology.org/page/go-slim-and-subset-guide and http://www.geneontology.org/ontology/subsets/goslim_chembl.obo). Targets can now be browsed by GO slim terms on the interface:



* HELM Notation

HELM Notations for monoclonal antibodies have been generated by Stefan Klostermann and team at Roche Diagnostics, and added to the database. In addition, HELM Notations have been generated for ~1100 new peptides that have been added to the ChEMBL_21 release.

* Improved Organism Classification

The organism classification has been enhanced for plant, insect and fungal targets to facilitate retrieval of crop protection data from the database. 


* RDF Update

ChEMBL 21 RDF files have been updated and can be downloaded from the ChEMBL-RDF ftpsite. The EBI-RDF Platform will be updated with the ChEMBL 21 RDF shortly.


We recommend you review the ChEMBL_21 release notes for a comprehensive overview of all updates and changes in ChEMBL 21, including schema changes, and as always, we greatly appreciate the reporting of any omissions or errors.

Keep an eye on the ChEMBL twitter and blog accounts for news and updates.

The ChEMBL Team






Comments

Unknown said…
This comment has been removed by the author.

Popular posts from this blog

ChEMBL_27 SARS-CoV-2 release

The COVID-19 pandemic has resulted in an unprecedented effort across the global scientific community. Drug discovery groups are contributing in several ways, including the screening of compounds to identify those with potential anti-SARS-CoV-2 activity. When the compounds being assayed are marketed drugs or compounds in clinical development then this may identify potential repurposing opportunities (though there are many other factors to consider including safety and PK/PD considerations; see for example https://www.medrxiv.org/content/10.1101/2020.04.16.20068379v1.full.pdf+html). The results from such compound screening can also help inform and drive our understanding of the complex interplay between virus and host at different stages of infection.
Several large-scale drug screening studies have now been described and made available as pre-prints or as peer-reviewed publications. The ChEMBL team has been following these developments with significant interest, and as a contribution t…

RDKit, C++ and Jupyter Notebook

Fancy playing with RDKit C++ API without needing to set up a C++ project and compile it? But wait... isn't C++ a compiled programming language? How this can be even possible?

Thanks to Cling (CERN's C++ interpreter) and xeus-cling jupyter kernel is possible to use C++ as an intepreted language inside a jupyter notebook!

We prepared a simple notebook showing few examples of RDKit functionalities and a docker image in case you want to run it.

With the single requirement of docker being installed in your computer you'll be able to easily run the examples following the three steps below:
docker pull eloyfelix/rdkit_jupyter_clingdocker run -d -p 9999:9999 eloyfelix/rdkit_jupyter_clingopen http://localhost:9999/notebooks/rdkit_cling.ipynb in a browser


FPSim2, a simple Python3 molecular similarity tool

FPSim2 is a new tool for fast similarity search on big compound datasets (>100 million) being developed at ChEMBL. We started developing it as we needed a Python3 library able to run either in memory or out-of-core fast similarity searches on such dataset sizes.

It's written in Python/Cython and features:
A fast population count algorithm (builtin-popcnt-unrolled) from https://github.com/WojciechMula/sse-popcount using SIMD instructions.Bounds for sub-linear speed-ups from 10.1021/ci600358fA compressed file format with optimised read speed based in PyTables and BLOSCUse of multiple cores in a single search In memory and on disk search modesSimple and easy to use
Source code is available on github and Conda packages are also available for either mac or linux. To install it type:

conda install rdkit -c rdkitconda install fpsim2 -c efelix
Try it with docker (much better performance than binder):

    docker pull eloyfelix/fpsim2    docker run -p 9999:9999 eloyfelix/fpsim2    open htt…

2019 and ChEMBL – News, jobs and birthdays

Happy New Year from the ChEMBL Group to all our users and collaborators. 
Firstly, do you want a new challenge in 2019?  If so, we have a position for a bioinformatician in the ChEMBL Team to develop pipelines for identifying links between therapeutic targets, drugs and diseases.  You will be based in the ChEMBL team but also work in collaboration with the exciting Open Targets initiative.  More details can be found here(closing date 24thJanuary). 
In case you missed it, we published a paper at the end of last on the latest developments of the ChEMBL database “ChEMBL: towards direct deposition of bioassay data”. You can read it here.  Highlights include bioactivity data from patents, human pharmacokinetic data from prescribing information, deposited data from neglected disease screening and data from the IMI funded K4DD project.  We have also added a lot of new annotations on the therapeutic targets and indications for clinical candidates and marketed drugs to ChEMBL.  Importantly we ha…

ChEMBL 25 and new web interface released

We are pleased to announce the release of ChEMBL 25 and our new web interface. This version of the database, prepared on 10/12/2018 contains:

2,335,417 compound records1,879,206 compounds (of which 1,870,461 have mol files)15,504,603 activities1,125,387 assays12,482 targets72,271 documents

Data can be downloaded from the ChEMBL ftp site: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25

Please see ChEMBL_25 release notes for full details of all changes in this release: ftp://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_25/chembl_25_release_notes.txt


DATA CHANGES SINCE THE LAST RELEASE

# Deposited Data Sets:

Kuster Lab Chemical Proteomics Drug Profiling (src_id = 48, Document ChEMBL_ID = CHEMBL3991601):
Data have been included from the publication: The target landscape of clinical kinase drugs. Klaeger S, Heinzlmeir S and Wilhelm M et al (2017), Science, 358-6367 (https://doi.org/10.1126/science.aan4368)

# In Vivo Assay Classification:

A classification…